Rare Disease Approvals Getting Easier
Regulators are streamlining orphan drug pathways. New incentives could accelerate your rare-disease portfolio across major markets.
Vladimir SimeonovNewsMar 2026
Home›News
All posts
Filter
STRATEGIES
AstraZeneca is set to showcase Phase III data in liver, breast, and bladder cancers at the ASCO Annual Meeting.
See more →
REGULATORY
New FDA guidance is reshaping approval timelines. Here's what commercial teams need to prepare for this quarter.
See more →
DISCOVERIES
Regulators are streamlining orphan drug pathways. New incentives could accelerate your rare-disease portfolio.
See more →
PRODUCTIVITY
How the move toward home-based care is changing field strategy for specialty and chronic-care brands.
See more →Regulators are streamlining orphan drug pathways. New incentives could accelerate your rare-disease portfolio across major markets.
Vladimir Simeonov
New FDA guidance is reshaping approval timelines. Here's what commercial teams need to prepare for.
Phase III data in liver, breast, and bladder cancers takes the spotlight at this year's ASCO meeting.
How home-based care is changing field strategy for specialty and chronic-care brands.
Get the latest pharma market intelligence, product updates, and strategy insights — straight to your inbox.